FMP
Lexaria Bioscience Corp.
LEXX
NASDAQ
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
1.39 USD
0.01 (0.719%)
Historical Prices
From:
To:
About
ceo
Mr. Richard C. Christopher
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectiv...
CIK
0001348362
ISIN
US52886N4060
CUSIP
52886N406
Address
100 – 740 McCurdy Road
Phone
250 765 6424
Country
CA
Employee
7
IPO Date
Jan 12, 2021
Financial Statement
Earnings
LEXX Financial Summary
CIK
0001348362
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
52886N406
ISIN
US52886N4060
Country
CA
Price
1.39
Beta
0.85
Volume Avg.
102.01k
Market Cap
24.41M
Shares
-
52-Week
1.15-4.44
DCF
-1.69
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.28
P/B
-
Website
https://www.lexariabioscience.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LEXX News
Gordon Thompson
Apr 3, 2025
Lexaria Bioscience Corp. (NASDAQ:LEXX) Earnings Preview and ...
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company known for its innovative drug delivery technology, DehydraTECH. This technology enhances the delivery of bioactive compounds, improving their effectiveness. LEXX is set to release its quarterly earnings on April 8, 2025, with Wall Street estimating an earnings per share of -$0.16 and projected revenue of approximately $137,000. LEXX is actively conducting a human study, GLP-1-H25-5, comparing oral DehydraTECH-liraglutide with inj...
Newsfile Corp
Mar 21, 2024
Lexaria to Present at The LD Micro Invitational XIV
Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
GuruFocus
Aug 23, 2023
Lexaria Bioscience Corp: A Comprehensive Stock Price Change ...
Lexaria Bioscience Corp ( LEXX , Financial), a biotechnology company, has seen significant changes in its stock price over the past three months. With a current market cap of $9.062 million and a stock price of $1.12, the company has experienced a price change of -3.60% over the past week and a substantial gain of 55.21% over the past three months.
InvestorPlace
May 9, 2023
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
Lexaria Bioscience (NASDAQ: LEXX ) stock is falling on Tuesday after the company revealed details about its public share offering. According to a press release, the LEXX public stock offering will include 2,106,000 units with each one containing one share and one warrant to purchase a share.
Schaeffers Research
Jul 29, 2022
9 Cannabis Stocks on Fire This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Benzinga
Jun 21, 2022
Why Shares Of Lexaria Biosciences Are Trading Higher
Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. The first agreement is a manufacturing operating agreement that expands production capabilities for Lexaria's own growing list of business-to-.
Benzinga
Apr 21, 2022
Lexaria Posied To Receive US Patent For DehydraTECH To Deliv...
Lexaria Bioscience Corp (NASDAQ: LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods.
InvestorPlace
Apr 14, 2022
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. The post Why Is Lexaria Bioscience (LEXX) Stock Up Today?
